The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Thrombin Time

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Thrombin Time


High impact information on Thrombin Time


Chemical compound and disease context of Thrombin Time


Biological context of Thrombin Time


Anatomical context of Thrombin Time


Associations of Thrombin Time with chemical compounds

  • A progressive delay in thrombin time was associated with increasing sialic acid content of the patient fibrinogen [22].
  • The anticoagulant prolonged the thrombin time but not the reptilase time and was resistant to boiling, proteolytic enzyme digestion, and trichloracetic acid precipitation [10].
  • Argatroban given alone increased thrombin time by 454 +/- 18% and aPTT by 160 +/- 3% [23].
  • The presence of the high affinity gamma' chain site on fibrinogen molecules did not inhibit fibrinogen conversion to fibrin as assessed by thrombin time measurements, and thrombin exosite binding to fibrin at either site did not inhibit its catalytic activity toward a small thrombin substrate, S-2238 [24].
  • Effects of phenformin on blood sugar, serum triglyceride, thrombin time, euglobulin clot lysis time and cardiovascular complications were studied in maturity onset diabetes and in atherosclerotic patients with or without diabetes, for a period of 14-18 months [25].

Gene context of Thrombin Time

  • In plasma of IBD patients significantly decreased tissue type plasminogen activator activity (t-PA) (p less than 0.02), increased plasminogen activator inhibition (PAI) (p less than 0.01) and fibrinogen (p less than 0.001), and prolonged thrombin time (p less than 0.001) and prothrombintime (p less than 0.001) were found [26].
  • Incubation on ice yielded a decrease to 45% of control, whereas alpha 2-antiplasmin was fully consumed at 37 degrees C. Fibrinogen and plasminogen fell to 46% and 39%, respectively, after a 30 min incubation at 25 degrees C. Thrombin time prolonged to 190% of control [27].
  • Activated partial thromboplastin time (APTT), thrombin time (TT), prothrombin time (PT) and tissue factor pathway inhibitor (TFPI) were higher after 8 p.m. injection than after 8 a.m. injection (p < 0.05) while no chrono-pharmacological variation of anti factor Xa (AXa) activity was observed [28].
  • Thrombin time dependently phosphorylated HSP27 at Ser-15 and Ser-85 while having no effect on the levels of HSP27 [29].
  • Patients exhibited lower ATIII, prolongation of the APTT and TT, but not PT or the reptilase time, which is a consequence of heparinization [30].

Analytical, diagnostic and therapeutic context of Thrombin Time


  1. Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition. Jang, I.K., Gold, H.K., Ziskind, A.A., Leinbach, R.C., Fallon, J.T., Collen, D. Circulation (1990) [Pubmed]
  2. The role of sialic acid in the dysfibrinogenemia associated with liver disease: distribution of sialic acid on the constituent chains. Martinez, J., MacDonald, K.A., Palascak, J.E. Blood (1983) [Pubmed]
  3. Acquired dysfibrinogenemia. Paraneoplastic syndrome in renal cell carcinoma. Dawson, N.A., Barr, C.F., Alving, B.M. Am. J. Med. (1985) [Pubmed]
  4. Coagulation assays as diagnostic markers of hepatocellular carcinoma. Lefrère, J.J., Conard, J., Mavier, P., Bettan, L., Beaugrand, M., Gozin, D., Lerable, J., Dhumeaux, D., Samama, M. Thromb. Haemost. (1988) [Pubmed]
  5. Intracranial hemorrhage and circulating coagulation inhibitor in beta-thalassemia major. Sinniah, D., Ekert, H., Bosco, J., Nathan, L., Koe, S.L. J. Pediatr. (1981) [Pubmed]
  6. The Passovoy defect: further characterization of a hereditary hemorrhagic diathesis. Hougie, C., Mc Pherson, R.A., Brown, J.E., Lakin-Thomas, P.L., Melaragno, A., Aronson, L., Baugh, R.F. N. Engl. J. Med. (1978) [Pubmed]
  7. Circulating thrombin time anticoagulant in a procainamide-induced syndrome. Galanakis, D.K., Newman, J., Summers, D. JAMA (1978) [Pubmed]
  8. Modulation of fibrin clot formation by human serum amyloid P component (SAP) and heparin. Ku, C.S., Fiedel, B.A. J. Exp. Med. (1983) [Pubmed]
  9. Isolation and study of an acquired inhibitor of human coagulation factor V. Nesheim, M.E., Nichols, W.L., Cole, T.L., Houston, J.G., Schenk, R.B., Mann, K.G., Bowie, E.J. J. Clin. Invest. (1986) [Pubmed]
  10. Circulating heparan sulfate proteoglycan anticoagulant from a patient with a plasma cell disorder. Khoory, M.S., Nesheim, M.E., Bowie, E.J., Mann, K.G. J. Clin. Invest. (1980) [Pubmed]
  11. Abnormal coagulation and fibrinolysis in eclampsia. A clinical and laboratory correlation study. López-Llera, M., de la Luz Espinosa, M., Diaz de León, M., Linares, G.R. Am. J. Obstet. Gynecol. (1976) [Pubmed]
  12. Absence of drug interaction between heparin and nitroglycerin. Randomized placebo-controlled crossover study. Bode, V., Welzel, D., Franz, G., Polensky, U. Arch. Intern. Med. (1990) [Pubmed]
  13. The effect of prophylaxis with low dose heparin on blood coagulation parameters. A double blind study in connection with transvesical prostatectomy. Hedlund, P.O., Blombäck, M. Thromb. Haemost. (1979) [Pubmed]
  14. Pharmacological profile of recombinant, human activated protein C (LY203638) in a canine model of coronary artery thrombosis. Jackson, C.V., Bailey, B.D., Shetler, T.J. J. Pharmacol. Exp. Ther. (2000) [Pubmed]
  15. Hydroxyethyl starch versus albumin in cardiopulmonary bypass prime solutions. Saunders, C.R., Carlisle, L., Bick, R.L. Ann. Thorac. Surg. (1983) [Pubmed]
  16. Assessment and characterization of degradation effect for the varied degrees of ultra-violet radiation onto the collagen-bonded polypropylene non-woven fabric surfaces. Tyan, Y.C., Liao, J.D., Klauser, R., Wu, I.e.D., Weng, C.C. Biomaterials (2002) [Pubmed]
  17. The effects of Hespan on serum and lymphatic albumin, globulin, and coagulant protein. Lucas, C.E., Denis, R., Ledgerwood, A.M., Grabow, D. Ann. Surg. (1988) [Pubmed]
  18. Histamine levels and cardiovascular responses during splenectomy and splenorenal shunt formation in a patient with systemic mastocytosis. Smith, G.B., Gusberg, R.J., Jordan, R.H., Kim, B. Anaesthesia. (1987) [Pubmed]
  19. Heparin-binding proteins are involved in thrombin time variability in normal and patient plasmas. Xiao, H., Miller, S., Faulk, W.P. Blood Coagul. Fibrinolysis (2000) [Pubmed]
  20. Protein-bound heparin/heparan sulfates in human adult and umbilical cord plasma. Xiao, H., Miller, S.J., Bang, N.U., Faulk, W.P. Haemostasis (1999) [Pubmed]
  21. Low dose calcium heparin in horses: plasma heparin concentrations, effects on red blood cell mass and on coagulation variables. Gerhards, H. Equine Vet. J. (1991) [Pubmed]
  22. Abnormal sialic acid content of the dysfibrinogenemia associated with liver disease. Martinez, J., Palascak, J.E., Kwasniak, D. J. Clin. Invest. (1978) [Pubmed]
  23. Combined administration of aspirin and a specific thrombin inhibitor in man. Clarke, R.J., Mayo, G., FitzGerald, G.A., Fitzgerald, D.J. Circulation (1991) [Pubmed]
  24. Identification and characterization of the thrombin binding sites on fibrin. Meh, D.A., Siebenlist, K.R., Mosesson, M.W. J. Biol. Chem. (1996) [Pubmed]
  25. Antifibrin action of phenformin. Banerjee, R.N., Kumar, V., Rao, S.R., Sahni, A.L., Arya, M., Bardhan, J. Diabetologia (1975) [Pubmed]
  26. Disturbed fibrinolysis in patients with inflammatory bowel disease. A study in blood plasma, colon mucosa, and faeces. de Jong, E., Porte, R.J., Knot, E.A., Verheijen, J.H., Dees, J. Gut (1989) [Pubmed]
  27. In vitro effects of urokinase--prevention by different inhibitors. Oethinger, M.D., Seifried, E. Thromb. Haemost. (1990) [Pubmed]
  28. Chrono-pharmacological study of once daily curative dose of a low molecular weight heparin (200 IU antiXa/kg of Dalteparin) in ten healthy volunteers. Mismetti, P., Reynaud, J., Tardy-Ponce, B., Laporte-Simitsidis, S., Scully, M., Goodwyn, C., Queneau, P., Decousus, H. Thromb. Haemost. (1995) [Pubmed]
  29. Midazolam suppresses thrombin-induced heat shock protein 27 phosphorylation through inhibition of p38 mitogen-activated protein kinase in cardiac myocytes. Tanabe, K., Akamatsu, S., Suga, H., Takai, S., Kato, K., Dohi, S., Kozawa, O. J. Cell. Biochem. (2005) [Pubmed]
  30. Haemostatic variables in patients with unstable angina. al-Nozha, M., Gader, A.M., al-Momen, A.K., Noah, M.S., Jawaid, M., Arafa, M. International journal of cardiology. (1994) [Pubmed]
  31. The appearance of donor heparin in the recipient after reperfusion of a liver graft. Bakker, C.M., Stibbe, J., Gomes, M.J., Groenland, T.N., Metselaar, H.J., Hesselink, E.J., Schalm, S.W., Terpstra, O.T. Transplantation (1993) [Pubmed]
  32. Effects of bacterial contamination of reagent water on selected laboratory tests. Batjer, J.D., Williamson, L.J., Polissar, L., Hamlin, W.B. Am. J. Clin. Pathol. (1979) [Pubmed]
  33. Heparin-loaded zein microsphere film and hemocompatibility. Wang, H.J., Lin, Z.X., Liu, X.M., Sheng, S.Y., Wang, J.Y. Journal of controlled release : official journal of the Controlled Release Society. (2005) [Pubmed]
  34. Monitoring of anticoagulation in aprotinin-treated patients during heart operation. Tabuchi, N., Njo, T.L., Tigchelaar, I., Huyzen, R.J., Boonstra, P.W., van Oeveren, W. Ann. Thorac. Surg. (1994) [Pubmed]
  35. Coagulation changes during the steady state in homozygous sickle-cell disease in Jamaica. Leslie, J., Langler, D., Serjeant, G.R., Serjeant, B.E., Desai, P., Gordon, Y.B. Br. J. Haematol. (1975) [Pubmed]
WikiGenes - Universities